Oncolytic Viruses: The Best is Yet to Come

Title:Oncolytic Viruses: The Best is Yet to Come

Volume: 18 Issue: 2

Author(s): Chantal G. Lemay, Brian A. Keller, Robert E. Edge, Masato Abei and John C. Bell*

Affiliation:

• Center for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON,Canada

Keywords: Cancer therapy, combination therapy, immunity, oncolytic viruses, tumour microenvironment, virotherapy.

Abstract: Oncolytic viruses are a promising anti-cancer platform, achieving significant pre-clinical and clinical milestones in recent years. A full arsenal of selective, safe, and effective viruses has been developed with some emerging pre-clinical research focusing on optimizing these therapies in the face of remaining challenges, both in the bloodstream and in the tumour microenvironment. Herein we discuss the recent progress in pre-clinical virotherapy research to address these challenges, with special focus on innovative strategies that seek to complement the current strengths of virotherapy, ensuring an optimal multi-faceted attack on cancer. This review highlights the research areas that we believe provide the most potential to increase the efficacy of this exciting biotherapy platform: cell carriers, tumour vascular destruction, microenvironment modulation, combination therapies, and virus-mediated anti-tumour immune responses.

Cite this article as:

Lemay G. Chantal, Keller A. Brian, Edge E. Robert, Abei Masato and Bell C. John*, Oncolytic Viruses: The Best is Yet to Come, Current Cancer Drug Targets 2018; 18(2) . https://dx.doi.org/10.2174/1568009617666170206111609